Literature DB >> 7832633

Identification of an N-linked glycan in the V1-loop of HIV-1 gp120 influencing neutralization by anti-V3 antibodies and soluble CD4.

G J Gram1, A Hemming, A Bolmstedt, B Jansson, S Olofsson, L Akerblom, J O Nielsen, J E Hansen.   

Abstract

Glycosylation is necessary for HIV-1 gp120 to attain a functional conformation, and individual N-linked glycans of gp120 are important, but not essential, for replication of HIV-1 in cell culture. We have constructed a mutant HIV-1 infectious clone lacking a signal for N-linked glycosylation in the V1-loop of HIV-1 gp120. Lack of an N-linked glycan was verified by a mobility enhancement of mutant gp120 in SDS-gel electrophoresis. The mutated virus showed no differences in either gp120 content per infectious unit or infectivity, indicating that the N-linked glycan was neither essential nor affecting viral infectivity in cell culture. We found that the mutated virus lacking an N-linked glycan in the V1-loop of gp120 was more resistant to neutralization by monoclonal antibodies to the V3-loop and neutralization by soluble recombinant CD4 (sCD4). Both viruses were equally well neutralized by ConA and a conformation dependent human antibody IAM-2G12. This suggests that the N-linked glycan in the V1-loop modulates the three-dimensional conformation of gp120, without changing the overall functional integrity of the molecule.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7832633     DOI: 10.1007/bf01310789

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  20 in total

1.  Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1.

Authors:  S S Hwang; T J Boyle; H K Lyerly; B R Cullen
Journal:  Science       Date:  1992-07-24       Impact factor: 47.728

Review 2.  Neutralization of HIV-1: a paradox of humoral proportions.

Authors:  P L Nara; R R Garrity; J Goudsmit
Journal:  FASEB J       Date:  1991-07       Impact factor: 5.191

3.  Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop.

Authors:  J P Moore; M Thali; B A Jameson; F Vignaux; G K Lewis; S W Poon; M Charles; M S Fung; B Sun; P J Durda
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

4.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.

Authors:  S Harada; Y Koyanagi; N Yamamoto
Journal:  Science       Date:  1985-08-09       Impact factor: 47.728

5.  Detection of HIV antigens in eluates from whole blood collected on filterpaper.

Authors:  C M Nielsen; I C Bygbjerg; B F Vestergaard
Journal:  Lancet       Date:  1987-03-07       Impact factor: 79.321

6.  Restricted expression of human T-cell leukemia--lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes.

Authors:  S Z Salahuddin; P D Markham; F Wong-Staal; G Franchini; V S Kalyanaraman; R C Gallo
Journal:  Virology       Date:  1983-08       Impact factor: 3.616

7.  Role of N-linked glycans of envelope glycoproteins in infectivity of human immunodeficiency virus type 1.

Authors:  E Fenouillet; J C Gluckman; E Bahraoui
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

8.  Carbohydrate determinant NeuAc-Gal beta (1-4) of N-linked glycans modulates the antigenic activity of human immunodeficiency virus type 1 glycoprotein gp120.

Authors:  A Bolmstedt; S Olofsson; E Sjögren-Jansson; S Jeansson; I Sjöblom; L Akerblom; J E Hansen; S L Hu
Journal:  J Gen Virol       Date:  1992-12       Impact factor: 3.891

9.  Recombinant CD4-selected human immunodeficiency virus type 1 variants with reduced gp120 affinity for CD4 and increased cell fusion capacity.

Authors:  J McKeating; P Balfe; P Clapham; R A Weiss
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

10.  Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization.

Authors:  A Koito; G Harrowe; J A Levy; C Cheng-Mayer
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

View more
  21 in total

1.  Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1.

Authors:  James Lue; Mayla Hsu; David Yang; Preston Marx; Zhiwei Chen; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

2.  Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1.

Authors:  Rong Rong; S Gnanakaran; Julie M Decker; Frederic Bibollet-Ruche; Jesse Taylor; Jeffrey N Sfakianos; John L Mokili; Mark Muldoon; Joseph Mulenga; Susan Allen; Beatrice H Hahn; George M Shaw; Jerry L Blackwell; Bette T Korber; Eric Hunter; Cynthia A Derdeyn
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

3.  Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.

Authors:  C Cheng-Mayer; A Brown; J Harouse; P A Luciw; A J Mayer
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

4.  Identification of two N-linked glycosylation sites within the core of the simian immunodeficiency virus glycoprotein whose removal enhances sensitivity to soluble CD4.

Authors:  Cheryl Pikora; Christine Wittish; Ronald C Desrosiers
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

5.  Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection.

Authors:  Rong Rong; Frederic Bibollet-Ruche; Joseph Mulenga; Susan Allen; Jerry L Blackwell; Cynthia A Derdeyn
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

6.  Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity.

Authors:  Ralph Pantophlet; Terri Wrin; Lisa A Cavacini; James E Robinson; Dennis R Burton
Journal:  Virology       Date:  2008-09-26       Impact factor: 3.616

7.  Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies.

Authors:  Eloìsa Yuste; Jacqueline Bixby; Jeffrey Lifson; Shuji Sato; Welkin Johnson; Ronald Desrosiers
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

8.  Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3.

Authors:  Kelly Stefano Cole; Jonathan D Steckbeck; Jennifer L Rowles; Ronald C Desrosiers; Ronald C Montelaro
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

9.  Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies.

Authors:  Alexey A Nabatov; Georgios Pollakis; Thomas Linnemann; Aletta Kliphius; Moustapha I M Chalaby; William A Paxton
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

10.  N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization.

Authors:  Tobias Wolk; Michael Schreiber
Journal:  Med Microbiol Immunol       Date:  2006-03-18       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.